F. Breillout

540 total citations
22 papers, 460 citations indexed

About

F. Breillout is a scholar working on Oncology, Molecular Biology and Cell Biology. According to data from OpenAlex, F. Breillout has authored 22 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Cell Biology. Recurrent topics in F. Breillout's work include Cancer Treatment and Pharmacology (11 papers), Microtubule and mitosis dynamics (6 papers) and Amino Acid Enzymes and Metabolism (4 papers). F. Breillout is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Microtubule and mitosis dynamics (6 papers) and Amino Acid Enzymes and Metabolism (4 papers). F. Breillout collaborates with scholars based in France, Belgium and Italy. F. Breillout's co-authors include M.F. Poupon, A Krikorian, Dominique Levêque, Élisabeth Quoix, F. Jehl, Guido F. Pauli, H. Monteil, G. Bastian, Saı̈k Urien and J.P. Tillement and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

In The Last Decade

F. Breillout

21 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Breillout France 12 236 175 108 64 61 22 460
Hiroshi Shirota Japan 11 103 0.4× 141 0.8× 15 0.1× 24 0.4× 49 0.8× 39 513
E Chinje United Kingdom 8 76 0.3× 195 1.1× 29 0.3× 41 0.6× 138 2.3× 11 394
David A. Litvak United States 12 221 0.9× 442 2.5× 25 0.2× 25 0.4× 85 1.4× 21 724
Xinghua Yuan China 12 167 0.7× 278 1.6× 20 0.2× 22 0.3× 81 1.3× 30 494
Danfeng Xue China 10 117 0.5× 367 2.1× 29 0.3× 10 0.2× 117 1.9× 15 604
Hye‐Rim Park South Korea 13 123 0.5× 340 1.9× 12 0.1× 30 0.5× 65 1.1× 37 530
Yuichi Koga Japan 12 170 0.7× 386 2.2× 15 0.1× 21 0.3× 105 1.7× 22 807
Philippe Reisdorf France 7 128 0.5× 262 1.5× 23 0.2× 13 0.2× 35 0.6× 7 386
Elisabeth Hedström Sweden 11 317 1.3× 517 3.0× 62 0.6× 13 0.2× 128 2.1× 15 684
Dean J. Welsch United States 13 158 0.7× 313 1.8× 13 0.1× 25 0.4× 188 3.1× 22 686

Countries citing papers authored by F. Breillout

Since Specialization
Citations

This map shows the geographic impact of F. Breillout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Breillout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Breillout more than expected).

Fields of papers citing papers by F. Breillout

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Breillout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Breillout. The network helps show where F. Breillout may publish in the future.

Co-authorship network of co-authors of F. Breillout

This figure shows the co-authorship network connecting the top 25 collaborators of F. Breillout. A scholar is included among the top collaborators of F. Breillout based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Breillout. F. Breillout is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Breillout, F., et al.. (2011). Effect of microtubule-targeting drugs on cell–cell and cell–matrix junctions in tumor epithelial cells. Anti-Cancer Drugs. 22(3). 234–244. 2 indexed citations
2.
Barret, Jean‐Marc, Charles Dumontet, F. Breillout, et al.. (2009). A functional procedure using fresh samples to select patients with acute myeloid leukemia prior to treatment with the novel targeted cytotoxic agent F14512. Journal of Clinical Oncology. 27(15_suppl). 11087–11087. 2 indexed citations
3.
Fahy, Jacques, Paul Hellier, F. Breillout, & Christian Bailly. (2008). Vinflunine: Discovery and Synthesis of a Novel Microtubule Inhibitor. Seminars in Oncology. 35(3 Suppl 3). S3–S5. 10 indexed citations
4.
Simoens, Cindy, Filip Lardon, Bea Pauwels, et al.. (2008). Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer. 8(1). 65–65. 21 indexed citations
5.
Simoens, Cindy, Bea Pauwels, Jan B. Vermorken, et al.. (2007). Further mechanistic unravelling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitro. Cancer Chemotherapy and Pharmacology. 62(2). 183–193. 3 indexed citations
6.
Simoens, Cindy, Jan B. Vermorken, A.E.C. Korst, et al.. (2005). Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro. Cancer Chemotherapy and Pharmacology. 58(2). 210–218. 21 indexed citations
7.
Filipski, Elisabeth, S. Amat, G Lemaigre, et al.. (1999). Relationship Between Circadian Rhythm of Vinorelbine Toxicity and Efficacy in P388-Bearing Mice. Journal of Pharmacology and Experimental Therapeutics. 289(1). 231–235. 28 indexed citations
8.
Allam, Nageh K., et al.. (1994). Characterisation of a navelbine-resistant bladder carcinoma cell line cross-resistant to taxoids. British Journal of Cancer. 70(6). 1118–1125. 12 indexed citations
9.
Allam, Nageh K., et al.. (1994). [Characterization of the mechanism of cross-resistance to vinca alkaloids and taxoids in the human J82 bladder tumor cell line].. PubMed. 81(10). 891–3. 1 indexed citations
10.
Zhou, Xiaojian, et al.. (1993). Pharmacokinetics of navelbine after oral administration in the dog and the monkey. Anti-Cancer Drugs. 4(4). 511–516. 3 indexed citations
11.
Urien, Saı̈k, et al.. (1993). Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemotherapy and Pharmacology. 32(3). 231–234. 40 indexed citations
12.
Berge, D. Van Den, et al.. (1993). 5'-Nor-anhydrovinblastine (Navelbine) has an anti-invasive effect on MO4 mouse fibrosarcoma cells in vitro and in vivo.. PubMed. 13(1). 273–7. 5 indexed citations
13.
Levêque, Dominique, F. Jehl, Élisabeth Quoix, & F. Breillout. (1992). Clinical Pharmacokinetics of Vinorelbine Alone and Combined with Cisplatin. The Journal of Clinical Pharmacology. 32(12). 1096–1098. 24 indexed citations
14.
Krikorian, A & F. Breillout. (1991). Vinorelbine (Navelbine®). A New Semisynthetic Vinca Alkaloid. Oncology Research and Treatment. 14(1). 7–12. 25 indexed citations
15.
Jehl, F., Élisabeth Quoix, Dominique Levêque, et al.. (1991). Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.. PubMed. 51(8). 2073–6. 68 indexed citations
16.
Breillout, F., et al.. (1990). Methionine Dependency of Malignant Tumors: A Possible Approach for Therapy. JNCI Journal of the National Cancer Institute. 82(20). 1628–1632. 96 indexed citations
17.
Breillout, F., et al.. (1989). Promotion of Micrometastasis Proliferation in a Rat Rhabdomyosarcoma Model by Epidermal Growth Factor. JNCI Journal of the National Cancer Institute. 81(9). 702–705. 11 indexed citations
18.
Breillout, F., et al.. (1988). Association of SIBA treatment and a Met-depleted diet inhibitsin vitro growth andin vivo metastatic spread of experimental tumor cell lines. Clinical & Experimental Metastasis. 6(1). 3–16. 18 indexed citations
19.
Breillout, F., et al.. (1987). Decreased rat rhabdomyosarcoma pulmonary metastases in response to a low methionine diet.. PubMed. 7(4B). 861–7. 50 indexed citations
20.
Judde, Jean‐Gabriel, et al.. (1987). Inhibition of Rat Natural Killer Cell Function by Carcinogenic Nickel Compounds: Preventive Action of Manganese<xref ref-type="fn" rid="FN2">2</xref>. JNCI Journal of the National Cancer Institute. 78(6). 1185–90. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroshi Shirota Breakdown of academic impact, for papers by E Chinje Breakdown of academic impact, for papers by David A. Litvak Breakdown of academic impact, for papers by Xinghua Yuan Breakdown of academic impact, for papers by Danfeng Xue Breakdown of academic impact, for papers by Hye‐Rim Park Breakdown of academic impact, for papers by Yuichi Koga Breakdown of academic impact, for papers by Philippe Reisdorf Breakdown of academic impact, for papers by Elisabeth Hedström Breakdown of academic impact, for papers by Dean J. Welsch
Rankless by CCL
2026